Novartis to gain heart drug in $1.4B deal for Tourmaline Bio

Tourmaline recently unveiled mid-stage trial data for its anti-inflammatory drug, which is ready for Novartis to advance into Phase 3 testing for heart disease.

NERC orders DisCos to adopt SOP to tackle meter bypass – EnviroNews

March 7, 2026

Regional workshop highlights Uruguay’s experience in phasing out dental amalgam – EnviroNews

March 7, 2026

Source link

Novartis to gain heart drug in $1.4B deal for Tourmaline Bio

NERC orders DisCos to adopt SOP to tackle meter bypass – EnviroNews

Regional workshop highlights Uruguay’s experience in phasing out dental amalgam – EnviroNews

New study shows that internet networks are growing in Africa, but high phone costs limit accessibility

‘The homeland is in the Pacific’

‘The homeland is in the Pacific’

Leave a Reply Cancel reply

RECOMMENDED NEWS

Career Progression: The 7-Point Plan to Guide You

Spirit shutters Morecambe Bay platform over fire safety fears

South Africa: Mantashe To Officially Open The Inaugural African Critical Minerals Summit

Toyota’s EV strategy hinges on a partnership with a petrochemical company

POPULAR NEWS

Mahama attends Liberia’s 178th independence anniversary

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

Novartis to gain heart drug in $1.4B deal for Tourmaline Bio

Related posts

New study shows that internet networks are growing in Africa, but high phone costs limit accessibility

‘The homeland is in the Pacific’

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS